Abstract:Since there are several limitations in cancer treatment for traditional chemotherapy, such as side effects, poor prognosis and drug resistance, developing new combined therapy is urgently needed. In this work, a biocompatible, simple and tumor microenvironment-responsive nanotheranostics (PCN-Oxpt/PEG) was built to favor the chemotherapy/ferroptosis/immunomodulation synergism in cancer. This nanotheranostics is constructed by modifying oxaliplatin prodrug and PEG on Fe(III) - porphyrin metal-organic frameworks (PCN(Fe) MOFs). After intravenous injection, the cloak of PEG leads to long circulation, and the Fe(III)-porphyrin MOFs enables dual-model guidance with fluorescence (FL) and magnetic resonance imaging (MRI). Inside the tumor, the intracellular H2O2 would be transferred into hydroxyl radicals (center dot OH) by iron ions released from MOFs, which could trigger the lethal ferroptosis to cancer cells. Meanwhile, oxaliplatin(II) transformed from the loaded oxaliplatin prodrug would result in the chemotherapy, as well as immunogenic cell death (ICD), and the prodrug strategy could also avoid the occurring of liver damage by the direct administration of oxaliplatin(II). It was noticed that the ferroptosis effect was enhanced by triple-assistance during the combined therapy, as followed: (1) glutathione (GSH) would be consumed in the process of oxaliplatin(II) generation from oxaliplatin prodrug; (2) the increased CD8(+) T cells induced by ICD were able to produce interferon-gamma (IFN-gamma), which could inhibit the transport of cystine by tumor cells, and impair the activation of glutathione peroxidase 4 (GPX4); (3) the amount of H2O2 could be increased by the internalized oxaliplatin and thus further promote the Fenton reaction and ferroptosis. Both in vivo and in vitro results revealed that tumor growing was significantly inhibited by PCN-Oxpt/PEG, taken together, the concomitant of oxaliplatin-mediated chemotherapy and ICD with triple-enhanced ferroptosis offer great prospect in the clinical treatment of cancer.

Iron-based metal-organic framework co-loaded with buthionine sulfoximine and oxaliplatin for enhanced cancer chemo-ferrotherapy via sustainable glutathione elimination

Dual GSH-exhausting Sorafenib Loaded Manganese-Silica Nanodrugs for Inducing the Ferroptosis of Hepatocellular Carcinoma Cells.

Targeted Gsh-Exhausting And Hydroxyl Radical Self-Producing Manganese-Silica Nanomissiles For Mri Guided Ferroptotic Cancer Therapy

Tumor microenvironments self-activated nanoscale metal-organic frameworks for ferroptosis based cancer chemodynamic/photothermal/chemo therapy

Iron (II)-based metal-organic framework nanozyme for boosting tumor ferroptosis through inhibiting DNA damage repair and system Xc-

A Fe(III)-porphyrin-oxaliplatin(IV) Nanoplatform for Enhanced Ferroptosis and Combined Therapy

An iron-based metal-organic framework nanoplatform for enhanced ferroptosis and oridonin delivery as a comprehensive antitumor strategy

Highly selective and effective ferroptosis liposomal nanodrugs for synergistic antitumor therapy

Glutathione-responsive and -exhausting metal nanomedicines for robust synergistic cancer therapy

A self-amplified ferroptosis nanoagent that inhibits the tumor upstream glutathione synthesis to reverse cancer chemoresistance

Activatable Plasmonic Versatile Nanoplatform for Glutathione-Depletion Augmented Ferroptosis and NIR-II Photothermal Synergistic Therapy

Tumor Microenvironment‐Activatable Metal‐Phenolic Nanoformulations for Ultrasound‐Boosted Ferroptosis through Triple Regulatory Pathways

Redox Responsive Metal Organic Framework Nanoparticles Induces Ferroptosis for Cancer Therapy

Spatially Asymmetric Nanoparticles for Boosting Ferroptosis in Tumor Therapy.

Biodegradable zwitterionic polymer-cloaked defective metal–organic frameworks for ferroptosis-inducing cancer therapy

Glutathione depletion and dihydroorotate dehydrogenase inhibition actuated ferroptosis-augment to surmount triple-negative breast cancer

The Composites of Triple-Helix Glucan Nanotubes/selenium Nanoparticles Target Hepatocellular Carcinoma to Enhance Ferroptosis by Depleting Glutathione and Augmenting Redox Imbalance

In vivo assembly enhanced binding effect augments tumor specific ferroptosis therapy

Lactic Acid Responsive Sequential Production of Hydrogen Peroxide and Consumption of Glutathione for Enhanced Ferroptosis Tumor Therapy

Fe-Mediated Self-Assembled Nanodrug for Tumor Microenvironment Activated Synergistic Ferroptosis-Based-Chemodynamic/Chemo Therapy and Magnetic Resonance Imaging

Manganese porphyrin-based metal-organic framework for synergistic sonodynamic therapy and ferroptosis in hypoxic tumors